代表性研究成果（按发表时间倒序排列）：
1. Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial. EClinicalMedicine.2025 Oct 31:90:103621. doi: 10.1016/j.eclinm.2025.103621.（IF=10.0）
2. Development of a DNA Aptamer-Based Approach to Noninvasively Image CAR-T Cells In Vivo and Traceless Enrichment In Vitro. Adv Sci (Weinh).2025 Jul;12(28):e2506746. doi: 10.1002/advs.202506746.（IF=14.1）
3. EF1α, rather than CMV promoter, is suitable for luciferase tag expression in target cells for in vitro cytotoxicity assays of CAR-T cells. Mol Ther Methods Clin Dev.2025 Jul 17;33(3):101537. doi: 10.1016/j.omtm.2025.101537.（IF=4.7）
4.Advances in CAR optimization strategies based on CD28.Front Immnunol.2025 Mar 13:16:1548772. doi: 10.3389/fimmu.2025.1548772.（IF=5.7）
5. IFN-γ-mediated suppression of Caspase 7 exacerbates acute lung injury induced by CAR-T cells. Mol Ther.2025 Jul 2;33(7):3392-3406. doi: 10.1016/j.ymthe.2025.03.023（IF=12.1）
6. Presetting CAR-T cells during ex vivo biomanufacturing. Mol Ther.2025 Apr 2;33(4):1380-1406. doi: 10.1016/j.ymthe.2025.02.031（IF=12.1）
7. Developing safe and efficient CGBE editor based on Cas-embedding strategy.Synth Syst Biotechnol.2025 Feb 6;10(2):504-510. doi: 10.1016/j.synbio.2025.02.001.（IF=4.8）
8. LILRB4 as a novel immunotherapeutic target for multiple diseases. Biochem Pharmacol.2025 Mar:233:116762. doi: 10.1016/j.bcp.2025.116762.（IF=4.8）
9. A new perspective on the therapeutic potential of tumor metastasis: targeting the metabolic interactions between TAMs and tumor cells. Int J Biol Sci.2024 Sep 23;20(13):5109-5126. doi: 10.7150/ijbs.99680. (IF = 8.2)
10. BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. 2024 May 23.“中国科技期刊卓越行动计划高起点新刊”https://doi.org/10.1016/j.hlife.2024.05.005
11. Expand available targets for CAR-T therapy to overcome tumor drug resistance based on the "Evolutionary Traps". Pharmacol Res.2024 Jun:204:107221. doi: 10.1016/j.phrs.2024.107221. (IF = 9.1)
12. Bispecific CAR T-cell therapy targeting BCMA and CD19in relapsed/refractory multiple myeloma: a phase l/l trial.Nature communications.2024 Apr 20;15(1):3371. doi: 10.1038/s41467-024-47801-8.（IF =16.6）
13. In vivo manufacture and manipulation of CAR T cells for better druggability. Cancer and Metastasis Reviews.2024 Sep;43(3):1075-1093. doi: 10.1007/s10555-024-10185-8.（IF = 9.2）
14. CRISPR screens in mechanism and target discovery for AML. Heliyon. 2024 Apr 9. doi: 10.1016/j.heliyon.2024.e29382.（IF =3.4）
15. Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors. BBA-Molecular Basis of Disease. 2024 Apr 5:167159. doi: 10.1016/j.bbadis.2024.167159.（IF = 6.2）
16. Bispecific BCMA/CD19 targeted CAR T cell therapy forces sustained disappearance ofsymptoms andanti acetylcholine receptor antibodies inrefractory myasthenia gravis: acase report.Journal of Neurology,2024 Apr11,doi.org/10.1007/s00415-024-12367-4（IF = 6.0）
17. AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses. Front Immnunol. 2023 Sep 12:14:1182601. doi: 10.3389/fimmu.2023.1182601.（IF =7.3）
18. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol. 2022 Jul 10;40(20):2246-2256.（IF = 45.3）
19. Safety and efficacy of a humanized CD19 chimeric antigen receptor T Cells for relapsed/refractory acute lymphoblastic leukaemia. Am J Hematol. 2022 Jun 1;97(6):711-718.（IF = 12.8）
20. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood. 2022 Jun 9;139(23):3376-3386.（IF = 20.3）
21. An immune-related gene prognostic risk index for pancreatic adenocarcinoma. Front Immnunol.2022,13:945878.（IF = 7.3）
22. Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated. J Immunother Cancer. 2021, 9(1):e001466.（IF = 10.9）
23. CRISPR screen in mechanism and target discovery for cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2020, 1874(1):188378.（IF = 11.2）
24. β2-AR activation promotes cleavage and nuclear translocation of Her2 and metastatic potential of cancer cells. Cancer Sci.2020,111(12):4417-4428.（IF = 5.7）
25. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019 Oct;6(10):e521-e529.（IF = 24.7）
26. Neural regulation of drug resistance in cancer treatment. Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):20-28.（IF =11.2）
